Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06477419 · ClinicalTrials.gov registry record · Phase 2
A Study of Sacituzumab Govitecan in People With Mesothelioma
A Phase 2 study of Mesothelioma and Mesotheliomas Pleural, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 7
- Study locations
NCT06477419 is a Phase 2 study of Mesothelioma and Mesotheliomas Pleural that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 33 participants, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (83% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT06477419, a Phase 2 study of Mesothelioma and Mesotheliomas Pleural, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 7
- Study locations
Study Summary
Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.
Conditions Studied
Interventions
- DRUG Sacituzumab govitecan-hziy
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center @ Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan - Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2029-06-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06477419
The ClinicalTrials.gov registry entry for NCT06477419 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (83% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Mesothelioma appearing as the primary indexed condition, and to 1 intervention - of which Sacituzumab govitecan-hziy is the first listed.
NCT06477419 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06477419 about?
NCT06477419 is a clinical study titled "A Study of Sacituzumab Govitecan in People With Mesothelioma". Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.
What is the current status of trial NCT06477419?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2024-06-21. Estimated completion is 2029-06-21.
What conditions does trial NCT06477419 study?
This clinical trial studies the following conditions: Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Pleura.
What interventions are being tested in trial NCT06477419?
The interventions under investigation include: Sacituzumab govitecan-hziy (DRUG).
Who is sponsoring clinical trial NCT06477419?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06477419 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olaparib in Patients With HRD Malignant Mesothelioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
RECRUITING · Phase 2
-
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
RECRUITING · Phase 2
-
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.